Investment Analysts’ Recent Ratings Updates for Eli Lilly and Company (LLY)

Several analysts have recently updated their ratings and price targets for Eli Lilly and Company (NYSE: LLY):

• 5/5/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Guggenheim. They now have a $1,183.00 price target on the stock.
• 5/4/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 5/4/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Wolfe Research. They now have a $1,325.00 price target on the stock.
• 5/4/2026 – Eli Lilly and Company had its price target raised by Barclays PLC from $1,350.00 to $1,400.00. They now have an “overweight” rating on the stock.
• 5/2/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $1,344.00 price target on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target lowered by Bank of America Corporation from $1,294.00 to $1,133.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,205.00 to $1,230.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target raised by The Goldman Sachs Group, Inc. from $1,260.00 to $1,283.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Eli Lilly and Company had its price target lowered by Leerink Partners from $1,296.00 to $1,058.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,163.00 to $1,183.00. They now have a “buy” rating on the stock.
• 4/10/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,313.00 to $1,327.00. They now have an “overweight” rating on the stock.
• 4/10/2026 – Eli Lilly and Company had its price target raised by Rothschild & Co Redburn from $875.00 to $880.00. They now have a “neutral” rating on the stock.
• 4/6/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/2/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,293.00 to $1,294.00. They now have a “buy” rating on the stock.
• 3/30/2026 – Eli Lilly and Company had its price target lowered by Guggenheim from $1,168.00 to $1,163.00. They now have a “buy” rating on the stock.
• 3/29/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 3/27/2026 – Eli Lilly and Company had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 3/21/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 3/18/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by UBS Group AG.
• 3/17/2026 – Eli Lilly and Company was downgraded by HSBC Holdings plc from “hold” to “reduce”. They now have a $850.00 price target on the stock, down from $1,070.00.
• 3/13/2026 – Eli Lilly and Company was given a new $1,300.00 price target by Jefferies Financial Group Inc.. They now have a “buy” rating on the stock.
• 3/10/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein.
• 3/7/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.